FDA expands teplizumab to children aged ≥1 year with stage 2 T1D, enabling earlier intervention to delay progression to insulin dependence.
Rachael Sood, RN, MSN, APRN, NP-C, CDCES
Advertisement
Rachael Sood, RN, MSN, APRN, NP-C, CDCES, is owner and CEO of The Diabetes Collective.
Articles by Rachael Sood, RN, MSN, APRN, NP-C, CDCES
Advertisement
Latest Updated Articles
Rachael Sood, RN, on the new expanded indication of teplizumabApril 22nd 2026
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes
2
How to recognize and when to refer for children with hidradenitis suppurativa
3
Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation
4
FDA news in pediatrics: May 2026
5